Wire · operational-macro
Lilly brings more heat to Novo with FDA nod for once-weekly insulin Onswik
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 September 2026 · Fusion42 review
The FDA has approved Eli Lilly's once-weekly basal insulin Onswik for type 2 diabetes, positioning it as a direct competitor to Novo Nordisk's recently launched Awiqli in the U.S. This approval follows prior regulatory wins in the EU, Mexico, and Japan and is based on clinical trials demonstrating non-inferior efficacy to daily insulins.
This Wire brief sits within Fusion42's coverage of Health, and 4 sources have reported it between 24 Sep 2026 and 26 Sep 2026.
◆ ◆ The Wire takeaway
The insulin market just opened a new battleground in the U.S. for you if you build diabetes treatments or platforms. Lilly's FDA approval of once-weekly insulin means the competitive race with Novo is accelerating and patient expectations for convenience will rise fast.
◆ Coverage
4 sources · first reported 24 Sep 2026 · latest 26 Sep 2026
◆ Related on Wire
◆ Topics